Vyome Biosciences, an innovation-driven dermatology company, today announced that it has closed Series B financing of US$ 8 million led by Sabre Partners, with existing Series A investors Kalaari Capital and Aarin Capital also co-investing. The company focuses on developing novel and break through treatments for hard to treat and refractory skin conditions such as persistent dandruff and skin fungal infections, resistant acne and other skin bacterial infections
Vyome was co-founded by Dr. Shiladitya Sengupta, assistant professor of Medicine at Harvard Medical School, Dr. Rajesh Gokhale, director of the Institute of Genomics & Integrative Biology in Delhi, N. Venkat, ex-CEO of Emami and President of Shantha Biotechnics and Rajiv Mantri Executive Director, Navam Capital.
Speaking on the occasion, N. Venkat, Co-Founder and CEO of Vyome said
This financing is a major landmark in Vyome’s journey to translate cutting edge science into differentiated products and innovative commercialization strategies, and gives the company substantial firepower to drive the completion of critical milestones of USFDA filings and Phase 1 & Phase 2 clinical research for some of its lead compounds and other development and commercialization efforts of its Rx and OTC pipeline.
Vyome is pioneering the development of ‘first in class’ Molecular Replacement Therapeutics, MRT™ for killing dandruff-causing fungus, new antibiotics using Dual Action Rational Therapeutics, DART™ Technology that kill resistant acne-causing bacteria, and has developed a robust global patent portfolio.
Led by Rajiv Maliwal, Sabre Partners was founded by a group of professionals and has invested over $300 million in India. Their most prominent investment was in restructuring Centurion Bank, which was subsequently sold to HDFC Bank. Sabre also has an infrastructure fund and a healthcare focused venture capital fund called ‘Spring Healthcare’, through which this investment in Vyome was made and through which Sabre has built a high quality healthcare and life sciences portfolio over the past 4 years. Rajiv Maliwal, Founder and Managing Partner, Sabre Partners said,
We are delighted to partner with a world-class team that is applying science and critical understanding of unmet needs to develop unique platform technologies and products for the $20 billion global dermatology market.
Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. This financing is an important milestone in Vyome’s pioneering effort to deliver and to create innovation-based products for global markets out of India.
Website: Vyome Biosciences
- Kalaari Capital
- Venture capital
- Aarin Capital
- Vyome Biosciences
- Shiladitya Sengupta
- Vyome Biosciences Private Limited
- Centurion Bank
- Navam Capital
- healthcare fund
- Raghunath Mashelkar
- Rajiv Mantri
- Rajiv Maliwal
- N. Venkat
- Rajesh Gokhale
- Padma Vibhushan
- Harvard Medical School
- Sabre Partners
- Institute of Genomics